Literature DB >> 2021948

The relationship between motility factor receptor internalization and the lung colonization capacity of murine melanoma cells.

H Watanabe1, I R Nabi, A Raz.   

Abstract

The in vitro motility of B16-F1 melanoma cells is enhanced by incubation with a monoclonal antibody against gp78, previously characterized as a motility factor receptor. This antibody was used to study the relationship between motility stimulation in vitro and metastatic ability in vivo in the B16-F1 and K-1735 murine melanoma systems. While both high- and low-metastatic variants exhibited enhanced in vitro motility in response to the anti-gp78 monoclonal antibody, only the high-metastatic cells exhibited an increased metastatic ability. Surface immunofluorescence of low-metastatic cells was distributed more diffusely compared to a highly localized patching of gp78 on high-metastatic cells, suggesting that the directed endocytosis of gp78 to form a single leading edge is related to the metastatic ability of a cell, while fluorescence-activated cell sorter analysis revealed decreased gp78 surface expression in high-metastatic clones. Priming of cells by preventing internalization of gp78-antibody complexes by pertussis toxin resulted in a marked enhancement of pulmonary metastases by the treated cells which was directly correlated with decreased surface expression of gp78 following washout of pertussis toxin. These results suggest that cell motility induced by motility factor receptor occupancy may play a role in the process of metastasis and that the ligand-receptor complex internalization from the cell surface is involved in control of cell kinesis during metastasis.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2021948

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  16 in total

Review 1.  Cellular motility and prostatic carcinoma metastases.

Authors:  J L Mohler
Journal:  Cancer Metastasis Rev       Date:  1993-03       Impact factor: 9.264

Review 2.  Autocrine factors, type IV collagenase secretion and prostatic cancer cell invasion.

Authors:  M E Stearns; M Stearns
Journal:  Cancer Metastasis Rev       Date:  1993-03       Impact factor: 9.264

3.  GP78 Cooperates with Dual-Specificity Phosphatase 1 To Stimulate Epidermal Growth Factor Receptor-Mediated Extracellular Signal-Regulated Kinase Signaling.

Authors:  Dhong Hyo Kho; Mohammed Hafiz Uddin; Madhumita Chatterjee; Andreas Vogt; Avraham Raz; Gen Sheng Wu
Journal:  Mol Cell Biol       Date:  2019-05-14       Impact factor: 4.272

4.  Differential purification of autocrine motility factor derived from a murine protein-free fibrosarcoma.

Authors:  H Watanabe; K Kanbe; M Chigira
Journal:  Clin Exp Metastasis       Date:  1994-03       Impact factor: 5.150

5.  Tumor cell motility and metastasis : Autocrine motility factor as an example of ecto/exoenzyme cytokines.

Authors:  S Silletti; S Paku; A Raz
Journal:  Pathol Oncol Res       Date:  1997-09       Impact factor: 3.201

Review 6.  Autocrine motility factor and its receptor: role in cell locomotion and metastasis.

Authors:  I R Nabi; H Watanabe; A Raz
Journal:  Cancer Metastasis Rev       Date:  1992-03       Impact factor: 9.264

7.  Autocrine motility factor stimulates the invasiveness of malignant cells as well as up-regulation of matrix metalloproteinase-3 expression via a MAPK pathway.

Authors:  Arayo Haga; Tatsuyoshi Funasaka; Yoshihiro Deyashiki; Avraham Raz
Journal:  FEBS Lett       Date:  2008-05-15       Impact factor: 4.124

Review 8.  Viral and cellular MARCH ubiquitin ligases and cancer.

Authors:  Xiaoli Wang; Roger A Herr; Ted Hansen
Journal:  Semin Cancer Biol       Date:  2008-10-02       Impact factor: 15.707

9.  Overexpression of autocrine motility factor receptor (AMFR) in NIH3T3 fibroblasts induces cell transformation.

Authors:  Yasuharu Onishi; Kazuhiro Tsukada; Jun Yokota; Avraham Raz
Journal:  Clin Exp Metastasis       Date:  2003       Impact factor: 5.150

Review 10.  Prognostic factors for bladder cancer.

Authors:  T Otto; M Goepel; K H Heider; H Rübben
Journal:  Urol Res       Date:  1995
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.